Connection

Co-Authors

This is a "connection" page, showing publications co-authored by Ioannis Trougakos and Efstathios Kastritis.
Connection Strength

1.802
  1. Comparative kinetics of SARS-CoV-2 anti-spike protein RBD IgGs and neutralizing antibodies in convalescent and naïve recipients of the BNT162b2 mRNA vaccine versus COVID-19 patients. BMC Med. 2021 08 23; 19(1):208.
    View in: PubMed
    Score: 0.241
  2. Antibody Response After Initial Vaccination for SARS-CoV-2 in Patients With Amyloidosis. Hemasphere. 2021 Aug; 5(8):e614.
    View in: PubMed
    Score: 0.239
  3. Insights to SARS-CoV-2 life cycle, pathophysiology, and rationalized treatments that target COVID-19 clinical complications. J Biomed Sci. 2021 Jan 12; 28(1):9.
    View in: PubMed
    Score: 0.231
  4. Evaluation of minimal residual disease using next-generation flow cytometry in patients with AL amyloidosis. Blood Cancer J. 2018 05 24; 8(5):46.
    View in: PubMed
    Score: 0.192
  5. Molecular responses to therapeutic proteasome inhibitors in multiple myeloma patients are donor-, cell type- and drug-dependent. Oncotarget. 2018 Apr 03; 9(25):17797-17809.
    View in: PubMed
    Score: 0.190
  6. Milder degenerative effects of Carfilzomib vs. Bortezomib in the Drosophila model: a link to clinical adverse events. Sci Rep. 2017 12 19; 7(1):17802.
    View in: PubMed
    Score: 0.187
  7. The neutralizing antibody response post COVID-19 vaccination in patients with myeloma is highly dependent on the type of anti-myeloma treatment. Blood Cancer J. 2021 08 02; 11(8):138.
    View in: PubMed
    Score: 0.060
  8. Kinetics of Anti-SARS-CoV-2 Antibody Responses 3 Months Post Complete Vaccination with BNT162b2; A Prospective Study in 283 Health Workers. Cells. 2021 07 30; 10(8).
    View in: PubMed
    Score: 0.060
  9. Low neutralizing antibody responses in WM, CLL and NHL patients after the first dose of the BNT162b2 and AZD1222 vaccine. Clin Exp Med. 2021 Jul 20.
    View in: PubMed
    Score: 0.060
  10. High Prevalence of Anti-PF4 Antibodies Following ChAdOx1 nCov-19 (AZD1222) Vaccination Even in the Absence of Thrombotic Events. Vaccines (Basel). 2021 Jul 01; 9(7).
    View in: PubMed
    Score: 0.060
  11. Low neutralizing antibody responses against SARS-CoV-2 in older patients with myeloma after the first BNT162b2 vaccine dose. Blood. 2021 07 01; 137(26):3674-3676.
    View in: PubMed
    Score: 0.060
  12. Recovery of Innate Immune Cells and Persisting Alterations in Adaptive Immunity in the Peripheral Blood of Convalescent Plasma Donors at Eight Months Post SARS-CoV-2 Infection. Microorganisms. 2021 Mar 06; 9(3).
    View in: PubMed
    Score: 0.058
  13. SARS-CoV-2 Infection Is Asymptomatic in Nearly Half of Adults with Robust Anti-Spike Protein Receptor-Binding Domain Antibody Response. Vaccines (Basel). 2021 Mar 02; 9(3).
    View in: PubMed
    Score: 0.058
  14. Seroprevalence of Antibodies against SARS-CoV-2 among the Personnel and Students of the National and Kapodistrian University of Athens, Greece: A Preliminary Report. Life (Basel). 2020 Sep 21; 10(9).
    View in: PubMed
    Score: 0.056
  15. Molecular mechanisms of carfilzomib-induced cardiotoxicity in mice and the emerging cardioprotective role of metformin. Blood. 2019 02 14; 133(7):710-723.
    View in: PubMed
    Score: 0.050
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.